LTA4H and cancer: Although there are studies reporting the identification of potential inhibitors targeting each of the four described enzymes, to date only LTA4H and PFK-2/FBPase-2 have inhibitors in active clinical development, and only the PFK-2/FBPase-2 inhibitor (PFK158) is being tested in cancer patients.